Core Viewpoint - EverQuote (EVER) shares have increased by 12.7% in the past four weeks, closing at $23.99, with a potential upside of 42.4% based on Wall Street analysts' mean price target of $34.17 [1] Price Targets and Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.79, indicating variability among analysts; the lowest estimate of $30 suggests a 25.1% increase, while the highest target of $38 indicates a potential surge of 58.4% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates - Analysts are optimistic about EverQuote's earnings prospects, as indicated by a positive trend in earnings estimate revisions; the Zacks Consensus Estimate for the current year has risen by 7.4% over the past month, with four estimates increasing and no negative revisions [11][12] - The company holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, which further supports the potential upside for the stock [13]

Group 1 - Viant Technology (DSP) closed at $15.08, with a 25.9% gain over the past four weeks, and a mean price target of $21.13 suggests a 40.1% upside potential [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $2.80, indicating variability among analysts; the lowest estimate is $18 (19.4% increase), while the highest is $26 (72.4% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 51.3% over the past month, indicating positive earnings prospects for DSP [11][12] Group 2 - DSP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] - The clustering of price targets with a low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]

Core Viewpoint - Natural Gas Services (NGS) shares have increased by 38% recently, with analysts suggesting a potential upside of 45.3% based on a mean price target of $36.25 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $5.97, indicating variability among analysts [2] - The lowest price target of $32 suggests a 28.3% increase, while the highest target of $45 indicates an 80.4% potential surge [2] - A low standard deviation signifies a high degree of agreement among analysts regarding price movement direction [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about NGS's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has risen by 18.6% over the past month, with no negative revisions [12] - NGS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]

Core Viewpoint - ESS Tech, Inc. (GWH) has experienced a bearish price trend, losing 14.7% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with selling pressure likely subsiding, which supports a bullish outlook for the stock [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, signaling that bears may be losing control over the price during a downtrend [4][5]. - The occurrence of a hammer pattern at the bottom of a downtrend suggests that bulls may have successfully halted further price declines, indicating a potential trend reversal [5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for GWH, which is a bullish indicator, as it typically leads to price appreciation in the near term [7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 6.8%, indicating that sell-side analysts expect better earnings than previously predicted [8]. - GWH currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [9].

Core Insights - Olo Inc. (OLO) shows potential as a strong investment due to significant revisions in earnings estimates, indicating an improving earnings outlook [1][9] - Analysts are increasingly optimistic about Olo's earnings prospects, which is expected to positively influence its stock price [2][3] - The Zacks Rank system, which rates stocks from 1 (Strong Buy) to 5 (Strong Sell), has a proven track record, with 1 ranked stocks averaging a +25% annual return since 2008 [3][8] Current-Quarter Estimate Revisions - For the current quarter, Olo is projected to earn $0.08 per share, reflecting a +60% increase from the same quarter last year [5] - In the last 30 days, two estimates for Olo have been revised upward while one has been revised downward, leading to a 150% increase in the Zacks Consensus Estimate [5] Current-Year Estimate Revisions - The full-year earnings estimate for Olo is $0.31 per share, representing a +40.91% change from the previous year [6] - Over the past month, one estimate has been revised upward with no negative revisions, resulting in a 92.86% increase in the consensus estimate [7] Favorable Zacks Rank - Olo currently holds a Zacks Rank 2 (Buy) due to positive estimate revisions, which suggests strong potential for stock performance [8] - Research indicates that stocks with Zacks Rank 1 and 2 significantly outperform the S&P 500 [8] Bottom Line - Olo's stock has gained 51.2% over the past four weeks, driven by solid estimate revisions, making it a candidate for portfolio addition [9]

Core Viewpoint - Edgewise Therapeutics, Inc. (EWTX) has received a Zacks Rank 2 (Buy) upgrade due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is primarily based on a company's changing earnings picture, specifically tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Edgewise Therapeutics reflects a positive outlook on its earnings, which could positively affect its stock price [4][6]. Impact of Earnings Estimates on Stock Prices - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, influencing their buying or selling actions, which subsequently affects stock prices [5]. Recent Performance of Edgewise Therapeutics - Edgewise Therapeutics is projected to earn -$1.82 per share for the fiscal year ending December 2025, indicating a year-over-year decline of 25.5% [9]. - Over the past three months, the Zacks Consensus Estimate for Edgewise Therapeutics has increased by 2.1%, suggesting a positive trend in earnings estimates [9]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of Edgewise Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11].

Core Viewpoint - Legacy Education Inc. (LGCY) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4][6]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Legacy Education Inc. projects earnings of $0.59 per share for the fiscal year ending June 2025, reflecting an 11.3% year-over-year increase [9]. - Over the past three months, the Zacks Consensus Estimate for the company has risen by 2.6%, indicating a trend of increasing earnings estimates [9]. Zacks Rating System - The Zacks rating system evaluates stocks based on earnings estimate revisions, categorizing them into five groups from Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell) [8]. - The system has a strong track record, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988, highlighting the effectiveness of earnings estimate revisions in predicting stock performance [8]. Market Implications - The upgrade to Zacks Rank 2 positions Legacy Education Inc. in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term due to favorable earnings estimate revisions [11]. - Rising earnings estimates are correlated with stock price movements, as institutional investors often adjust their valuations based on these estimates, leading to buying or selling actions that affect stock prices [5][6].

Shares of Rambus (RMBS) have gained 23.3% over the past four weeks to close the last trading session at $56.35, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $72.25 indicates a potential upside of 28.2%.The mean estimate comprises eight short-term price targets with a standard deviation of $9.97. While the lowest estimate of $55 indicates a 2.4% decline from the current price ...

Shares of CI&T Inc. (CINT) have gained 21.5% over the past four weeks to close the last trading session at $6.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $8.23 indicates a potential upside of 34.9%.The mean estimate comprises eight short-term price targets with a standard deviation of $1.33. While the lowest estimate of $6.50 indicates a 6.6% increase from the current pr ...

Core Viewpoint - West Pharmaceutical Services (WST) has seen a 7.3% increase in share price over the past four weeks, closing at $216.64, with a potential upside of 31.1% based on Wall Street analysts' mean price target of $284 [1] Price Targets and Analyst Consensus - The average of 10 short-term price targets ranges from a low of $245 to a high of $355, with a standard deviation of $34.94, indicating variability in estimates [2] - The lowest estimate suggests a 13.1% increase, while the highest points to a 63.9% upside, highlighting the range of analyst expectations [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about WST's earnings prospects, as evidenced by a trend of higher EPS estimate revisions [11] - The Zacks Consensus Estimate for the current year has risen by 1.9% over the past month, with five estimates increasing and no negative revisions [12] - WST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]